Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance

Pancreatic cancer is one of the most deadly cancers, ranking amongst the top leading cause of cancer related deaths in developed countries. Features such as dense stroma microenvironment, abnormal signaling pathways, and genetic heterogeneity of the tumors contribute to its chemoresistant characteri...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 683788
Main Authors Xelwa, Ntombikayise, Candy, Geoffrey Patrick, Devar, John, Omoshoro-Jones, Jones, Smith, Martin, Nweke, Ekene Emmanuel
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.06.2021
Subjects
chemoresistance
chemotherapy
growth factors
Oncology
pancreatic cancer
signaling pathways
chemoresistance
pancreatic cancer
signaling pathways
growth factors
chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Pancreatic cancer is one of the most deadly cancers, ranking amongst the top leading cause of cancer related deaths in developed countries. Features such as dense stroma microenvironment, abnormal signaling pathways, and genetic heterogeneity of the tumors contribute to its chemoresistant characteristics. Amongst these features, growth factors have been observed to play crucial roles in cancer cell survival, progression, and chemoresistance. Here we review the role of the individual growth factors in pancreatic cancer chemoresistance. Importantly, the interplay between the tumor microenvironment and chemoresistance is explored in the context of pivotal role played by growth factors. We further describe current and future potential therapeutic targeting of these factors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Kwong Tsang, Precision Biologics, Inc., United States
Reviewed by: Massimo Fantini, Precision Biologics, Inc., United States; Paul B. Fisher, Virginia Commonwealth University, United States
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.683788